Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermatoses. Triamcinolone is more commonly seen in the forms triamcinolone hexacetonide, triamcinolone acetonide, and triamcinolone diacetate.
Triamcinolone was granted FDA approval on 3 December 1957. In October 2021, a suspension of triamcinolone acetonide was approved for suprachoroidal injection - the first suprachoroidal injection to receive FDA approval - for the treatment of patients with macular edema associated with uveitis.
肾上腺皮质激素类药。主要用于过敏性与自身免疫性炎症性疾病。由于本品潴钠作用较弱,故一般不用作肾上腺皮质功能减退的替代治疗。
National Eye Institute (NEI), Bethesda, Maryland, United States
Dean A. McGee Eye Institute, Oklahoma City, Oklahoma, United States
Edward Hines Jr. VAH, Hines, Illinois, United States
Manhattan Eye, Ear & Throat Hospital, New York, New York, United States
Save Sight Institute, Sydney/Sydney Eye Hospital Campus, University of Sydney, Sydney, New South Wales, Australia
Eye Care Centre, Vancouver, British Columbia, Canada
Save Sight Institute, Sydney/Sydney Eye Hospital Campus, University of Sydney, Sydney, New South Wales, Australia
Save Sight Institute, Sydney/Sydney Eye Hospital Campus, University of Sydney, Sydney, New South Wales, Australia
Sanofi-Aventis, Inc., Bridgewater, New Jersey, United States
National Eye Institute (NEI), Bethesda, Maryland, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.